3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Interventions
Paclitaxel
4
pembrolizumab
2
pazopanib
2
efatutazone
2
Sorafenib
2
Radiotherapy, Intensity-Modulated
2
trametinib
1
tislelizumab
1
surufatinib
1
spartalizumab
1
sapanisertib
1
lenvatinib
1
fosbretabulin
1
dabrafenib
1
crolibulin
1
combretastatin
1
cabozantinib
1
atezolizumab
1
abemaciclib
1
Taxes
1
Imatinib Mesylate
1
Gefitinib
1
Doxorubicin
1
Docetaxel
1
Cisplatin
1
Carboplatin
1
CUDC-907
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Thyroid Carcinoma, Anaplastic
×
combretastatin
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts